BRWA
NBIX icon

B. Riley Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

B. Riley Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,370
Closed -$297K – 816
2019
Q1 		$297K Buy
+3,370
New +$282K 0.04% 501
2018
Q4 		– Sell
-2,935
Closed -$362K – 711
2018
Q3 		$362K Buy
2,935
+20
+0.7% +$2.27K 0.04% 436
2018
Q2 		$288K Buy
+2,915
New +$261K 0.04% 483

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

B. Riley Wealth Advisors's NBIX Position: Q2 2019 in Review

B. Riley Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2019, closing a stake of 3,370 shares — an estimated $297K sold.

B. Riley Wealth Advisors first reported a position in NBIX in Q2 2018 and held it in 3 quarters. The position peaked at $362K in Q3 2018. 302 funds tracked by Wall St. Rank hold NBIX as of Q2 2019.

  • B. Riley Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q2 2019 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 3,370 Neurocrine Biosciences shares in Q2 2019, an estimated $297K.
  • B. Riley Wealth Advisors first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 3 quarters.
  • B. Riley Wealth Advisors's Neurocrine Biosciences position peaked at $362K in Q3 2018.
  • 302 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2019.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2019, filed 5 Aug 2019.